Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: Lack of prediction in HER2-positive disease treated with targeted therapy

A. Giordano, M. Giuliano, M. De laurentiis, G. Arpino, S. Jackson, B. C. Handy, N. T. Ueno, E. Andreopoulou, R. H. Alvarez, V. Valero, S. De placido, G. N. Hortobagyi, J. M. Reuben, M. Cristofanilli

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Circulating tumor cells (CTCs) are associated with inferior prognosis in metastatic breast cancer (MBC). We hypothesized that the relationship between CTCs and disease subtype would provide a better understanding of the clinical and biologic behavior of MBC. Patients and methods: We retrospectively analyzed 517 MBC patients treated at a single institution. Subtypes of primary tumors were analyzed by immunohistochemical (IHC) or fluorescent in situ hybridization analyses and CTCs were enumerated by CellSearch ® at starting a new therapy. Overall survival (OS) and progression-free survival durations for each IHC subtype were determined. Results: At a median follow-up of 24.6 months, 276 of 517 (53%) patients had died. The median OS for patients with

Original languageEnglish
Pages (from-to)1144-1150
Number of pages7
JournalAnnals of Oncology
Volume23
Issue number5
DOIs
Publication statusPublished - May 2012

Keywords

  • Circulating tumor cells
  • HER2
  • Immunohistochemical subtypes
  • Metastatic breast cancer
  • Tumor markers

ASJC Scopus subject areas

  • Oncology
  • Hematology

Fingerprint

Dive into the research topics of 'Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: Lack of prediction in HER2-positive disease treated with targeted therapy'. Together they form a unique fingerprint.

Cite this